| Item Type | Name |
|
Concept
|
Atherosclerosis
|
|
Academic Article
|
Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia.
|
|
Academic Article
|
What kinds of data should be available to probe the effects of nutrients, food supplements or vitamins on serum lipoprotein levels and/or atherosclerosis?
|
|
Academic Article
|
Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
|
|
Academic Article
|
The safety and immunogenicity of a CETP vaccine in healthy adults.
|
|
Academic Article
|
Overview of prevention and treatment of atherosclerosis with lipid-altering therapy for pharmacy directors.
|
|
Academic Article
|
Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives.
|
|
Academic Article
|
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
|
|
Academic Article
|
Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels.
|
|
Academic Article
|
Effect of ACAT inhibition on the progression of coronary atherosclerosis.
|
|
Academic Article
|
Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.
|
|
Academic Article
|
Underappreciated opportunities for low-density lipoprotein management in patients with cardiometabolic residual risk.
|
|
Academic Article
|
Medical and cost burden of atherosclerosis among patients treated in routine clinical practice.
|
|
Academic Article
|
Usefulness of increased skin cholesterol to identify individuals at increased cardiovascular risk (from the Predictor of Advanced Subclinical Atherosclerosis study).
|
|
Academic Article
|
Atherosclerosis surrogate imaging trials come of age: for better or for worse?
|
|
Academic Article
|
Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
|
|
Academic Article
|
Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
|
|
Academic Article
|
Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.
|
|
Academic Article
|
Apolipoprotein measurements: is more widespread use clinically indicated?
|
|
Academic Article
|
The incremental value of lipids and inflammatory biomarkers in determining residual cardiovascular risk.
|
|
Academic Article
|
Rosuvastatin in elderly patients.
|
|
Academic Article
|
Is it over for ezetimibe?
|
|
Academic Article
|
Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.
|
|
Academic Article
|
Effects of dietary supplementation with marine lipid concentrate on the plasma lipoprotein composition of hypercholesterolemic patients.
|
|
Academic Article
|
Update on CETP inhibition.
|
|
Academic Article
|
Therapies targeting exogenous cholesterol uptake: new insights and controversies.
|
|
Academic Article
|
Indicators of the atherogenic lipoprotein phenotype measured with density gradient ultracentrifugation predict changes in carotid intima-media thickness in men and women.
|
|
Academic Article
|
The effects of colestipol tablets compared with colestipol granules on plasma cholesterol and other lipids in moderately hypercholesterolemic patients.
|
|
Academic Article
|
Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis.
|
|
Academic Article
|
Pharmacological approaches to modifying HDL: more basic science to understand HDL metabolism is necessary. Editorial to: "NO-1886 up-regulates Niemann-Pick C1 protein (NPC1) expression through liver X receptor alpha signaling pathway in THP-1 macrophage-derived foam cells" by Xin Ma et al.
|
|
Academic Article
|
Inhibition of intestinal cholesterol absorption with ezetimibe increases components of reverse cholesterol transport in humans.
|
|
Academic Article
|
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
|
|
Academic Article
|
ETC-1002: a future option for lipid disorders?
|
|
Academic Article
|
Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial.
|
|
Academic Article
|
[Official document of the International Society of Atherosclerosis: general recommendations for treatment of dyslipidemia. Executive summary].
|
|
Academic Article
|
Carotid adventitial vasa vasorum and intima-media thickness in a primary prevention population.
|
|
Academic Article
|
Therapeutic ultrasound: Increased HDL-Cholesterol following infusions of acoustic microspheres and apolipoprotein A-I plasmids.
|
|
Academic Article
|
Changing characteristics of statin-related cIMT trials from 1988 to 2006.
|
|
Academic Article
|
Can We Cure Atherosclerosis?
|
|
Academic Article
|
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials).
|
|
Academic Article
|
Triglyceride-rich lipoprotein cholesterol (TRL-C): the ugly stepsister of LDL-C.
|
|
Academic Article
|
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.
|
|
Academic Article
|
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.
|
|
Academic Article
|
Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis.
|
|
Academic Article
|
How I treat statin-associated side effects in an outpatient setting.
|
|
Academic Article
|
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments.
|